S
Salomon M. Stemmer
Researcher at Rabin Medical Center
Publications - 215
Citations - 12740
Salomon M. Stemmer is an academic researcher from Rabin Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 43, co-authored 189 publications receiving 9651 citations. Previous affiliations of Salomon M. Stemmer include University of New South Wales & Tel Aviv University.
Papers
More filters
Journal ArticleDOI
Amifostine (WR-2721) shortens the engraftment period of 4- hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support
Elizabeth J. Shpall,Salomon M. Stemmer,Lisa Hami,Wilbur A. Franklin,Leslie M. Shaw,Heather S. Bonner,Scott I. Bearman,William P. Peters,Robert C. Bast,William McCulloch,R. Capizzi,Edith Mitchell,Philip S. Schein,Roy B. Jones +13 more
TL;DR: Ex vivo treatment of marrow with amifostine significantly shortens the time to marrow recovery, thereby reducing the risk of myelosuppressive complications in breast cancer patients receiving high- dose chemotherapy and 4-HC-purged ABMS.
Journal ArticleDOI
Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature
Dana Bielopolski,Ella Evron,Osnat Moreh-Rahav,Michal Landes,Salomon M. Stemmer,Francis Salamon +5 more
TL;DR: Clinicians should be aware of the potentially life-threatening risk of pulmonary toxicity following paclitaxel treatment, and if pac litaxel is halted early and the patient has good lung reserve, pulmonary toxicity can be reversed with high-dose steroid administration.
Journal Article
High-Dose 90Y Mx-Diethylenetriaminepentaacetic Acid (DTPA)-BrE-3 and Autologous Hematopoietic Stem Cell Support (AHSCS) for the Treatment of Advanced Breast Cancer: A Phase I Trial
David M. Schrier,Salomon M. Stemmer,Timothy Johnson,Ravindra Kasliwal,James L. Lear,S. Matthes,Sharon Taffs,Christopher Dufton,Stephan D. Glenn,Gregory Butchko,Robert L. Ceriani,Douglas Rovira,Paul A. Bunn,Elizabeth J. Shpall,Scott I. Bearman,Malcom Purdy,Pablo J. Cagnoni,Roy B. Jones +17 more
TL;DR: This Phase I trial explores the use of high-dose 90Y conjugated to the antibreast cancer monoclonal antibody BrE-3 and autologous hematologic cell support in the treatment of women with stage four breast cancer.
Journal ArticleDOI
Stereotactic body radiation therapy (SBRT) for definitive treatment and as a bridge to liver transplantation in early stage inoperable Hepatocellular carcinoma.
Assaf Moore,Michal Cohen-Naftaly,Michal Cohen-Naftaly,Anna Tobar,Anna Tobar,Yulia Kundel,Yulia Kundel,Ofer Benjaminov,Ofer Benjaminov,Marius Braun,Marius Braun,Assaf Issachar,Assaf Issachar,Eytan Mor,Eytan Mor,Michal Sarfaty,Michal Sarfaty,Dimitri Bragilovski,Ran Ben Hur,Noa Gordon,Salomon M. Stemmer,Salomon M. Stemmer,Aaron M. Allen,Aaron M. Allen +23 more
TL;DR: SBRT is safe and effective and can be used as a bridge to transplantation without comprising the surgical procedure, as well as well tolerated.
Journal ArticleDOI
Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial
Christoph C. Zielinski,István Láng,Moshe Inbar,Zsuzsanna Kahán,Richard Greil,Semir Beslija,Salomon M. Stemmer,Zanete Zvirbule,Günther G. Steger,Bohuslav Melichar,Tadeusz Pienkowski,Daniela Sirbu,Lubos Petruzelka,Alexandru Eniu,Bella Nisenbaum,M. Dank,Rodica Anghel,Diethelm Messinger,Thomas Brodowicz +18 more
TL;DR: Final results of the study aiming to show non-inferior overall survival with first-line bevacizumab plus capecitabine versus beVacizUMab plus paclitaxel in the per-protocol population by rejecting the null hypothesis of inferiority using a stratified Cox proportional hazard model are reported.